| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/20/2001 | WO2001096298A2 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 12/20/2001 | WO2001096296A1 Serine protease inhibitors |
| 12/20/2001 | WO2001096286A2 Urokinase inhibitors |
| 12/20/2001 | WO2001096285A1 Beta-amino acid nitrile derivatives |
| 12/20/2001 | WO2001096262A1 Method for producing dendritic structures |
| 12/20/2001 | WO2001095946A2 Combination product for carrying out a cytotoxic treatment in a mammal |
| 12/20/2001 | WO2001095945A2 Prodrug compounds cleavable by thimet oligopeptidase |
| 12/20/2001 | WO2001095943A2 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 12/20/2001 | WO2001095942A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | WO2001095937A2 Phytoestrogenic isoflavone compositions |
| 12/20/2001 | WO2001095936A2 Monoterpenes and sesquiterpenes as radiation sensitizers |
| 12/20/2001 | WO2001095935A1 Immunostimulatory nucleic acids for inducing a th2 immune response |
| 12/20/2001 | WO2001095934A2 The use of plant oil-bodies in vaccine delivery systems |
| 12/20/2001 | WO2001095929A2 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095923A1 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 12/20/2001 | WO2001095919A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| 12/20/2001 | WO2001095917A2 Kefir extract as an anti-cancer agent |
| 12/20/2001 | WO2001095908A1 Protoberberine derivatives which inhibit activity of the mitogen-activated protein kinase |
| 12/20/2001 | WO2001095899A2 Pharmaceutical compositions comprising cannabidiol derivatives |
| 12/20/2001 | WO2001095884A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds |
| 12/20/2001 | WO2001095785A2 Modulation of immune response and methods based thereon |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001079259A8 Javelinization of protein antigens to heat shock proteins |
| 12/20/2001 | WO2001077107B1 Oxazole derivatives and their uses as tyrosine kinase inhibitors |
| 12/20/2001 | WO2001066550A3 Compounds for pdt |
| 12/20/2001 | WO2001064164A3 Nanocapsule encapsulation system and method |
| 12/20/2001 | WO2001058896A8 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 12/20/2001 | WO2001052874A3 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 12/20/2001 | WO2001049689A3 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM |
| 12/20/2001 | WO2001046389A3 Immature autologous clinical grade dendritic cells intended for vaccination of cancer patients |
| 12/20/2001 | WO2001044207A3 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 12/20/2001 | WO2001035937A3 Lipid complex of alkycyclines |
| 12/20/2001 | WO2001031016A3 Processed human chemokines phc-1 and phc-2 |
| 12/20/2001 | WO2001019770A3 Rxr modulators with improved pharmacologic profile |
| 12/20/2001 | WO2001016108A3 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 12/20/2001 | WO2001010426A3 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 12/20/2001 | WO2000068387A3 Nucleic acids and proteins with interferon-beta activity |
| 12/20/2001 | WO2000060076A3 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 12/20/2001 | WO2000058358A9 49 human secreted proteins |
| 12/20/2001 | US20010053853 Alkanoic acid derivative; integrin receptor antagonist |
| 12/20/2001 | US20010053845 Anthracycline analogues bearing latent alkylating substituents |
| 12/20/2001 | US20010053844 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/20/2001 | US20010053784 Imminoribitol PNP inhibitors, preparation thereof and use thereof |
| 12/20/2001 | US20010053782 Pyrrolo[2,3-d]pyrimidine compounds |
| 12/20/2001 | US20010053778 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 12/20/2001 | US20010053774 Non-steroidal ligands for the estrogen receptor |
| 12/20/2001 | US20010053768 Gene therapy using replication competent targeted adenoviral vectors |
| 12/20/2001 | US20010053764 Interleukin-1 inhibitors in the treatment of diseases |
| 12/20/2001 | US20010053763 Method and composition for modulating an immune response |
| 12/20/2001 | US20010053759 Skin cancer preventive agent |
| 12/20/2001 | US20010053538 Biologically active synthetic thyrotropin and cloned gene for producing same |
| 12/20/2001 | US20010053536 cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor |
| 12/20/2001 | US20010053371 Molecule having an IL13-moiety and a cytotoxic moiety; especially for reducing growth of glioblastoma multiforme cells. |
| 12/20/2001 | US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors |
| 12/20/2001 | US20010053357 Peptide having an amino acid sequence corresponding to an amino acid sequence of a V-domain of a receptor for advanced glycation endproduct. |
| 12/20/2001 | US20010053355 Treated monocytes incubated to maximize number of functional dendritic cells; then incubated with disease effector agents to enhance the presentation of at least one disease-causing antigen expressed by the disease effector agents. |
| 12/20/2001 | US20010053352 Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | DE10128250A1 New hydrolytically stable glycolipid compounds having an alpha-C, N or S glycoside bond, useful as anticancer agents and immunostimulants |
| 12/20/2001 | DE10029433A1 New rhodomycinone compounds, e.g. ditrisarubicin I and cytorhodin Y, useful as anticancer agents, prepared by culturing new actinomycete strain |
| 12/20/2001 | DE10029014A1 Urokinase inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative |
| 12/20/2001 | DE10028402A1 New pyridinylamino-alkanoyl-glycyl-beta-alanine derivatives, are integrin inhibitors useful for treating, e.g. thrombosis, cardiac infarction, coronary heart disease, inflammation, tumors, osteoporosis or restenosis |
| 12/20/2001 | DE10024171A1 Neuronale Serin-Threonin-Protein-Kinase Neuronal serine threonine protein kinase |
| 12/20/2001 | CA2417131A1 Kefir extract as an anti-cancer agent |
| 12/20/2001 | CA2413149A1 Prodrug compounds with isoleucine |
| 12/20/2001 | CA2413077A1 Interferon for treatment of multiple sclerosis |
| 12/20/2001 | CA2412979A1 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 12/20/2001 | CA2412842A1 Combination product for carrying out a cytotoxic treatment in a mammal |
| 12/20/2001 | CA2412632A1 Hmg-coa reductase inhibitors and method |
| 12/20/2001 | CA2412579A1 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | CA2412462A1 6,5-fused bicyclic heterocycles |
| 12/20/2001 | CA2412316A1 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 12/20/2001 | CA2412257A1 Pro-apoptotic fragments of the dengue virus envelope glycoproteins |
| 12/20/2001 | CA2412223A1 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | CA2412165A1 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | CA2411967A1 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 12/20/2001 | CA2411965A1 The use of plant oil-bodies in vaccine delivery systems |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2411813A1 Tricyclic compounds as mrp1-inhibitors |
| 12/20/2001 | CA2411805A1 Serine protease inhibitors |
| 12/20/2001 | CA2411798A1 Serine protease inhibitors |
| 12/20/2001 | CA2411495A1 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 12/20/2001 | CA2411472A1 Cd154 variants |
| 12/20/2001 | CA2411346A1 Biosynthetic oncolytic molecules and uses therefor |
| 12/20/2001 | CA2411278A1 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | CA2411116A1 Indole derivatives and their use as 15-lipoxygenase inhibitors |
| 12/20/2001 | CA2411036A1 Combinatorial production of nucleotide and nucleoside (xitp)analogues |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/20/2001 | CA2396871A1 Immunostimulatory nucleic acids for inducing a th2 immune response |
| 12/19/2001 | EP1164198A1 Method for screening anticancer agent |
| 12/19/2001 | EP1164140A1 Novel sulfofucosylacylglycerol derivatives and utilization thereof as drugs |
| 12/19/2001 | EP1164139A1 Novel sulforhamnosylacylglycerol derivatives and utilization thereof as drugs |
| 12/19/2001 | EP1164138A1 Terpyridine-platinum (II) complexes |
| 12/19/2001 | EP1164136A1 Long wavelength absorbing bacteriochlorin alkyl ether analogs |
| 12/19/2001 | EP1164135A1 Substituted metal-phthalocyanines, their preparation and the use thereof |
| 12/19/2001 | EP1163909A2 Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine |